WASHINGTON — House progressives on Wednesday called for executives from six drug companies to appear on Capitol Hill next week to justify what the lawmakers termed unjustifiable price increases — the latest public display of displeasure from the Democratic Party’s left flank regarding House Speaker Nancy Pelosi’s approach to lowering pharmaceutical costs.

The companies include four brand-name drug manufacturers: Merck, Eli Lilly, Gilead, and Pfizer, a spokeswoman said. The progressives also invited executives from two generic manufacturers: Mylan, the manufacturer of EpiPen, and Mallinckrodt, a company accused of paying bribes to boost sales of a treatment for a rare seizure disorder in infants. Mylan is also among the companies implicated in a sweeping price-fixing lawsuit filed by dozens of state attorneys general.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy